Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 19;11(8):660. doi: 10.1038/s41419-020-02877-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Expression levels of CDKN2B-AS1 among KIRC (normal = 72, tumor = 518), KICH (normal = 25, tumor = 66) and KIRP (normal = 30, tumor = 197) patient samples in TCGA cohort using Wanderer software (P-value calculated by Mann–Whitney two-tailed test). b Expression of CDKN2B-AS1 in TCGA-KIRC cohort among different grades (normal = 72, grade 1–2 = 214, grade 3–4 = 268) and stages (normal = 72, stage I–II = 288 and stage III–IV = 203). c Overall survival in TCGA-KIRC cohort as performed by Kaplan–Meier analysis (using UALCAN software). d Relative expression levels of lncRNA CDKN2B-AS1 in RCC cell lines ACHN and Caki1. e Expression CDKN2B-AS1 in matched pairs of RCC tissue samples from SFVAMC cohort (P-value calculated by Mann–Whitney two-tailed test). f Receiver operating curve (ROC) analysis on SFVAMC cohort showing ability of lncRNA CDKN2B-AS1 to differentiate between malignant and non-malignant samples (SFVAMC cohort). g Predicted binding sites of miR-141 in CDKN2B-AS1 sequence. h Luciferase assays showing decreased reporter activity after co-transfection with either wild-type (WT), off-target (OT) CDKN2B-AS1 or luciferase control constructs (EV) with miR-CON/miR-141 in ACHN and Caki1 cells.